RJFSA
AMLX icon

Raymond James Financial Services Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,773
Closed -$250K – 3258
2022
Q4 		$250K Buy
+6,773
New +$240K ﹤0.01% 2710

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Raymond James Financial Services Advisors's AMLX Position: Q1 2023 in Review

Raymond James Financial Services Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2023, closing a stake of 6,773 shares — an estimated $250K sold.

Raymond James Financial Services Advisors first reported a position in AMLX in Q4 2022 and held it in 1 quarter. The position peaked at $250K in Q4 2022. 147 funds tracked by Wall St. Rank hold AMLX as of Q1 2023.

  • Raymond James Financial Services Advisors reported no remaining Amylyx Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 6,773 Amylyx Pharmaceuticals shares in Q1 2023, an estimated $250K.
  • Raymond James Financial Services Advisors first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Amylyx Pharmaceuticals position peaked at $250K in Q4 2022.
  • 147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2023, filed 14 Apr 2023.